Pharmacology at IgMin Research | Medicine Group

Our mission is to foster interdisciplinary dialogue and accelerate the advancement of knowledge across a wide spectrum of scientific domains.


Pharmacology is a crucial discipline within medical and biological sciences that examines the effects of drugs and substances on living organisms. This field investigates how various compounds interact with biological systems to produce therapeutic or adverse effects. By studying pharmacological mechanisms, researchers develop safer and more effective medications, contributing to improved patient care and well-being.

The study of pharmacology encompasses a diverse range of topics, including pharmacokinetics (drug absorption, distribution, metabolism, and excretion), pharmacodynamics (mechanisms of drug action), and toxicology (effects of substances on health). Pharmacologists work to understand the molecular targets of drugs, optimize dosages, and develop strategies to mitigate adverse effects. This knowledge is essential for advancing medical treatments and ensuring patient safety.

  • Clinical Pharmacology
  • Pharmacokinetics
  • Pharmacodynamics
  • Drug Discovery
  • Drug Development
  • Toxicology
  • Pharmacogenomics
  • Neuropharmacology
  • Cardiovascular Pharmacology
  • Oncology Pharmacology
  • Psychopharmacology
  • Immunopharmacology
  • Antibiotics and Antimicrobial Agents
  • Herbal and Natural Product Pharmacology
  • Pharmacovigilance
  • Pharmaceutical Chemistry
  • Molecular Pharmacology
  • Pharmacotherapy
  • Pain Pharmacology
  • Pediatric Pharmacology
  • Geriatric Pharmacology
  • Reproductive Pharmacology
  • Respiratory Pharmacology
  • Gastrointestinal Pharmacology
  • Environmental Pharmacology

Medicine Group (1)

Research Article Article ID: igmin187

Open Access Policy refers to a set of principles and guidelines aimed at providing unrestricted access to scholarly research and literature. It promotes the free availability and unrestricted use of research outputs, enabling researchers, students, and the general public to access, read, download, and distribute scholarly articles without financial or legal barriers. In this response, I will provide you with an overview of the history and latest resolutions related to Open Access Policy.

Examining the Causal Connection between Lipid-lowering Medications and Malignant Meningiomas through Drug-target Mendelian Randomization Analysis
by Liantai SongXiaoyan Guo, Wenhui Zhang, Mengjie Li, Xinyi Wu, Ziqian Kou, Yuxin Wang, Zigeng Ren and Qian Xu

Objectives: This study aims to investigate the causal link between the use of statins, a type of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, and the risk of developing malignant meningiomas, which are aggressive and recurrent tumors of the central nervous system with limited treatment options.M...ethods: Using Mendelian Randomization (MR) analysis, the study explored the relationship between genetic variants related to the expression of lipid-lowering drug targets (HMGCR, PCSK9, NPC1L1, and APOB) and malignant meningiomas. The analysis utilized data from Genome-Wide Association Studies (GWAS) and expression quantitative trait loci (eQTL) databases, with a focus on the genetic homogeneity of the Finnish population. Instrumental variables for the MR analysis were derived from significant eQTLs for the mentioned drug targets.Results: The MR analysis found a significant association between genetic variants linked to HMGCR inhibitor (statin) exposure and a reduced risk of malignant meningiomas. Specifically, an increased expression of the HMGCR gene in the blood was associated with lower susceptibility to malignant meningiomas (Odds Ratio [OR] = 2.57, 95% Confidence Interval [CI] = 1.05 - 6.31; p = 0.039). No significant associations were observed for other lipid-lowering drug targets.Conclusion: Preliminary evidence suggests that statin use may lower the risk of developing malignant meningiomas, indicating a potential therapeutic benefit for managing this type of cancer. However, further research, including clinical trials, is necessary to confirm these findings and understand the mechanisms behind the protective effect of statins against malignant meningiomas.

Pharmacology Molecular Medicine